Archives — February 2015 back to current month (6)
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island. The most fabulous fundamentals in the world won't propel a stock against powerful global or industry-wide headwinds. In this interview with The Life Sciences Report, Higgins, an industry veteran, discusses his methods of finding winning plays in the biotech space, and selects three names that could spike the punch in your portfolio.
Immuno-oncology—disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it—took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in 2015, bolstered by new drug approvals, new targets and new combination immunotherapies that increase potency. In this interview with The Life Sciences Report, Dunn outlines how companies large and small are leveraging these therapies, and where investors should look for opportunity in the sector.
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based in Canada, where resource stocks have absorbed so much investment capital that many healthcare names have remained hidden and undervalued. In this interview with The Life Sciences Report, Martin highlights a group of companies with superior growth prospects and room to run.
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which created the BioShares Biotechnology Clinical Trials and BioShares Biotechnology Products exchange-traded funds to limit risk. In this interview with The Life Sciences Report, McDonald describes how funds can be designed to grow on product sales and data generated via milestones in clinical development, and also names four companies he's included in the two portfolios.
"Under Margaret Hamburg's watch, the FDA instituted a slew of programs designed to speed up the review process for new drugs, and 2014 saw the agency approve a 20-year-record 51 novel therapies."
Buy on the Biotech Dip (02/05/2015)
"Biotechs are still on the rampage. Feeble market in January? Biotechs don't care. They just kept bulldozing forward. In fact, biotechs were some of the only stocks popping to start the year."
|"We are initiating coverage on RVX with a Buy rating."|
|"Q3/17 was, by far, VIVE's strongest, with 47 U.S. console placements."|
|"RXII's sd-rxRNA can augment already amazing results in immunotherapy."|